Linkedin
RLS logo_header
Linkedin

Myris Therapeutics Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer

Myris Therapeutics has a novel pipeline of ultra-high DAR ADC oncology medicines, developed using the company’s deep expertise in polymer chemistry and cancer biologics. Myris’ technology enables the development of ADCs with DAR50-300, meaning Myris can put 50-300 copies of the drug payload per antibody which is 10-100x higher than current standards. “This dramatically expands the range of possible payloads and precision therapy opportunities. Moreover, there are many clinically-validated small molecules that have previously not been amenable to use in ADCs because of their pharmacology or therapeutic index,” said Laura Benjamin, PhD, CEO of Myris Therapeutics. “We are advancing promising clinical candidates by utilizing innovative, yet proven, antibodies and payloads. Our emerging preclinical data suggest that we will see the expected improvement in efficacy and tolerability that the field so desperately needs.”

Read the full story on "Myris Therapeutics Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer"

Share:

More News

FDA accepts sBLA for Opdivo + Yervoy for Patients with Unresectable or Metastatic MSI-H or MRD CRC

“Today’s milestone brings us one step closer to providing an effective dual immunotherapy treatment option to adult and pediatric patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer,” said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. “We look forward to potentially bringing

FDA clears IND application for LTZ-301 to treat R/R NHL

“The FDA’s clearance, signaling the initiation of our Phase I study for LTZ-301, represents a significant milestone for the company,” said Robert Li, Ph.D., Founder and CEO of LTZ. “We look forward to advancing our lead asset into the clinic to evaluate our myeloid engager approach and its potential as

Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline

“Eikon has made remarkable progress in advancing a pivotal-stage clinical pipeline and early-stage development program powered by our single-molecule tracking technology and the deep expertise of our multidisciplinary team. With clinical studies now operating in 28 countries, across 5 continents, we are accelerating the development of much-needed therapies while continuing

First New Subject Dosed in Ph 2 Study of Ampligen and Imfinzi Combination Therapy for Late-Stage Pancreatic Cancer

AIM CEO Thomas K. Equels stated: “Unlike with many pancreatic cancer studies where accrual can be a major obstacle, we expect to continue to enroll subjects in Phase 2 of DURIPANC at a steady pace.”

Onco-This-Week

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.